Multiple Sclerosis in Children: Clinical, Diagnostic, and Therapeutic Aspects

International Review of Neurobiology

Volumn 79, Issue , 2007, Pages 269-279

  Rostásy, Kevin ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; HUMAN; MULTIPLE SCLEROSIS; PEDIATRICS; PRESCHOOL CHILD; REVIEW;

CHILD; CHILD, PRESCHOOL; HUMANS; MULTIPLE SCLEROSIS; PEDIATRICS;

EID: 34248653467     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)79011-6     Document Type: Review

References (52)

1. Amato M.P., Ponziani G., Bartolozzi M.L., and Siracusa G. A prospective study on the natural history of multiple sclerosis: Clues to the conduct and interpretation of clinical trials. J. Neurol. Sci. 168 (1999) 96-106
2. Balassy C., Bernert G., Wober-Bingol C., Csapo B., Kornek B., Szeles J., Fleischmann D., and Prayer D. Long-term MRI observation of childhood-onset relapsing-remitting multiple sclerosis. Neuropediatrics 32 (2001) 28-37
3. Boiko A., Vorobeychik G., Paty D., Devonshire V., Sadovnick D., and UBC MS Clinic Neurologists. Early onset multiple sclerosis. A longitudinal study. Neurology 59 (2002) 1006-1010
4. Bruhn H., Frahm J., Merboldt K.D., Hänicke W., Hanefeld F., Christen H.J., Kruse B., and Bauer H.J. Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann. Neurol. 32 (1992) 140-150
5. Dale R.C., and Branson J.A. Acute disseminated encephalomyelitis or multiple sclerosis: Can the initial presentation help in establishing a correct diagnosis. Arch. Dis. Child 90 (2005) 636-639
6. Dale R.C., de Sousa C., Chong W.K., Cox T.C., Harding B., and Nevile B.G. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123 (2000) 2407-2422
7. Dean G., and Elian M. Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 63 (1997) 565-568
8. Deryck O., Ketelaer P., and Dubois B. Clinical characteristic and long term prognosis in early onset multiple sclerosis. J. Neurol. 253 (2006) 720-723
9. Duquette P., Murray T.J., Pleines J., Ebers G.C., Sadovnick D., Weldon P., Warren S., Paty D.W., Upton A., Hader W., Nelson R., Auty A., et al. Multiple sclerosis in childhood: Clinical profile in 125 patients. J. Pediatr. 111 (1987) 359-363
10. Ghezzi A., Deplano V., Faroni J., Grasso M.G., Liguori M., Marrosu G., Pozzilli C., Simone I.L., and Zaffaroni M. Multiple sclerosis in childhood: Clinical features of 149 patients. Mult. Scler. 3 (1997) 43-46
11. Ghezzi A., Pozzilli C., Liguori M., Marrosu M.G., Milani N., Milanese C., Simone I., and Zaffaroni M. Prospective study of multiple sclerosis with early onset. Mult. Scler. 8 (2002) 115-118
12. Ghezzi A., Ruggieri M., Trojano M., Filippi M., and ITEMS Study Group. Italian studies on early-onset multiple sclerosis: The present and the future. Neurol. Sci. 24 (2004) S346-S349
13. Gusev E., Boiko A., Bikova O., Maslova O., Guseva M., Boiko S., Vorobeichik G., and Paty D. The natural history of early onset multiple sclerosis: Comparison of data from Moscow and Vancouver. Clin. Neurol. Neurosurg. 104 (2002) 203-207
14. Hahn C.D., Shroff M.M., Blaser S.I., and Banwell B.L. MRI criteria for multiple sclerosis. Evaluation in a pediatric cohort. Neurology 62 (2004) 806-808
15. Hanefeld F., Bauer H.J., Christen H.J., Kruse B., Bruhn H., and Frahm J. Multiple sclerosis in childhood: Report of 15 cases. Brain Dev. 13 (1991) 410-416
16. Hartung H.P., Gonsette R., Konig N., Kwiecinski H., Guseo A., Morrissey S.P., Krapf H., and Zwingers T. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
17. Hohol M.J., Olek M.J., Orav E.J., Stazzone L., Hafler D.A., Khoury S.J., Dawson D.M., and Weiner H.L. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease. Mult. Scler. 5 (1999) 403-409
18. Jansen P.H., van der Knaap M.S., and de Coo I.F. Leber's hereditary optic neuropathy with the 11778 mtDNA mutation and white matter disease resembling multiple sclerosis: Clinical, MRI and MRS findings. J. Neurol. Sci. 135 (1996) 176-180
19. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., and Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 57 (2001) S16-S24
20. Keegan M., Konig F., McClelland R., Bruck W., Morales Y., Bitch A., Panitch H., Lassmann H., Weinshenker B., Rodriguez M., Parisi J., and Lucchinetti C.F. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366 (2005) 579-582
21. Kornek B., Bernert G., Balassy C., Geldner J., Prayer D., and Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 34 (2003) 120-126
22. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., and Brueck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decrease over time. Brain 125 (2002) 2202-2212
23. Lennon V.A., Wingerchuk D.M., Krytzer T.J., Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., and Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica. Lancet 364 (2004) 2106-2112
24. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.-P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., et al. Recommended diagnostic criteria multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
25. Menge T., Hemmer B., Nessler S., Wiendl H., Neuhaus O., Hartung H.P., Kieseier C., and Stüve O. Acute disseminated encephalomyelitis: An update. Arch. Neurol. 62 (2005) 1673-1680
26. Mikaeloff Y., Moreau T., Debouverie M., Pelletier J., Lebrun C., Gout O., Pedespan J.-M., Van Hulle C., Vermersch P., and Ponsot G. Interferon β treatment in patients with childhood-onset multiple sclerosis. J. Pediatr. 139 (2001) 443-446
27. Mikaeloff Y., Suissa S., Vallee L., Lubetzki C., Ponsot G., Confavrfux C., and Tardieu M. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for multiple sclerosis and disability. J. Pediat. 144 (2004) 246-252
28. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W., and International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing-remitting multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
29. Namaka M., Pollitt-Smith M., Gupta A., Klowak M., Vasconcelos M., Turcotte D., Gong Y., and Melanson M. The clinical importance of neutralizing antibodies in relapsing-remitting sclerosis. Curr. Med. Res. Opin. 22 (2006) 223-239
30. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
31. Ozakbas S., Idiman E., Baklan B., and Yulug B. Childhood and juvenile onset multiple sclerosis: Clinical and paraclinical features. Brain Dev. 25 (2003) 233-236
32. Peterson J.W., Bo L., Mork S., Chang A., and Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
33. Pittock S.J., Lennon V.A., Krecke K., Wingerchuk D.M., Lucchinetti C.F., and Weinshenker B.G. Brain abnormalities in neuromyelitis optica. Arch. Neurol. 63 (2006) 390-396
34. Pohl D., Rostasy K., Reiber H., and Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology 63 (2004) 1966-1967
35. Pohl P., Rostasy K.M., Gärtner J., and Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon-beta-1a. Neurology 64 (2005) 88-890
36. Pohl P., Krone B., Rostasy K., Kahler E., Brunner E., Lehnert M., Wagner H.J., Gärtner J., and Hanefeld F. Pediatric multiple sclerosis and Epstein-Barr virus: High seroprevalence and antibody titers. Neurology 67 11 (2006) 2063-2065
37. Pohl P., Hennemuth I., von Kries R., and Hanefeld F. Pediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: Results of a nationwide survey. Eur. J. Pediatr. (2006) (Epub ahead of print)
38. Pohl P., Rostasy K., Treiber-Held S., Brockmann K., Gärtner J., and Hanefeld F. Pediatric multiple sclerosis: Detection of clinically silent lesions by multimodal evoked potentials. J. Pediatr. 149 (2006) 125-127
39. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria.". Ann. Neurol. 58 (2005) 840-846
40. Polman C., O'Connor P., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 899-910
41. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
42. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-1a in relapsing MS. Neurology 56 (2001) 1628-1636
43. Rostasy K., Kolb R., Pohl D., Mueller H., Fels C., Moers A.V., Bergmann M., Hanefeld F., Pekrun A., and Schulz-Schaeffer W. CNS disease as the main manifestation of hemophagocytic lymphohistiocytosis in two children. Neuropediatrics 35 (2004) 45-49
44. Rostasy K., Withut E., Pohl D., Lange P., Ciesielcyk B., Diehm R., Gärtner J., and Otto M. Tau phospho-tau and S-100B protein in cerebrospinal fluid of children with multiple sclerosis. J. Child Neurol. 20 (2005) 822-825
45. Rudick R., Stuart W., Calabresi P., Confavreux C., Galetta S.L., Radue E.W., Lublin F.D., Weinstock-Guttman B., Wynn D.R., Lynn F., Panzara M.A., Sandrock A.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006) 911-923
46. Ruggieri M., Iannetti P., Polizzi A., Pavone L., and Grimaldi L.M.E. Multiple sclerosis in children under 10 years of age. Neurol. Sci. 25 (2004) S326-S335
47. Schilling S., Linker R.A., Konig F.B., Koziolek M., Bahr M., Muller G.A., Paulus W., Gartner J., Bruck W., Chan A., and Gold R. Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: Clinical experience with 16 patients. Nervenarzt 77 (2006) 430-438
48. Simone I.L., Carrara D., Tortorella C., Liguori M., Lepore V., Pellegrini F., Bellacosa A., Ceccarelli A., Pavone I., and Livrea P. Course and prognosis in early-onset MS. Comparison with adult-onset forms. Neurology 59 (2002) 1922-1928
49. Singh S., Prabhakar S., Korah I.P., Warade S.S., and Alexander M. Acute disseminated encephalomyelitis and multiple sclerosis: Magnetic resonance imaging findings. Australas Radiol. 44 (2000) 404-411
50. Tenembaum S.N., and Segura M.J. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 67 (2006) 511-513 (expedited E-Pub)
51. Trapp B.D., Jeterson J., Ransohoff R.M., Rudick R., Moerk S., and Boe L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
52. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 112 (1989) 133-146